Birch Pollen Allergy – Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type –

Pollen Allergy – Pipeline Review, H1 2019”
drug pipelines has
been added to’s offering.

Birch Pollen Allergy – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Birch Pollen Allergy (Immunology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key
players involved in therapeutic development for Birch Pollen Allergy and
features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Preclinical and Discovery stages are 2,
2, 3 and 2 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Birch Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Birch Pollen
    Allergy (Immunology) by companies and universities/research institutes
    based on information derived from company and industry-specific
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
  • The pipeline guide reviews key companies involved in Birch Pollen
    Allergy (Immunology) therapeutics and enlists all their major and
    minor projects.
  • The pipeline guide evaluates Birch Pollen Allergy (Immunology)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Birch Pollen Allergy (Immunology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Birch Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Birch Pollen Allergy (Immunology) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Dec 13, 2018: Anergis reports positive preclinical proof-of concept
    data of the Second-Generation COP Allergy Vaccine
  • Sep 05, 2018: Anergis initiates development of second-generation COP
    Allergy Vaccines; announces publication of sustained efficacy data
    from Ph. IIb study follow-Up
  • Aug 14, 2018: HAL Allergy first company to achieve marketing
    authorisations in line with Therapieallergene-Verordnung (TAV) in
  • May 27, 2018: Allergy experts: Clinical effect of ALK’s tree
    SLIT-tablet among the most significant ever seen in allergy
    immunotherapy trials
  • Jun 14, 2017: Desentum has two presentations in EAACI 2017
  • May 10, 2017: Desentum is preparing to start clinical trials with
    birch pollen allergy vaccine
  • Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited
    in Pivotal Phase III Birch Immunotherapy B301 Study
  • May 17, 2016: HAL Allergy has successfully completed its Phase III
    short-term efficacy trial with its sublingual allergen immunotherapy
    (SLIT) liquid product for the treatment of birch pollen allergy
  • May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results
    From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic
  • Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose
    ranging study in Germany and Austria
  • Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study
    Results in an Approved, Accelerated up-dosing Regimen
  • May 12, 2013: Desentum: EARTO innovation prize to VTT
  • Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomays
    Bet v 1

Companies Mentioned

  • ALK-Abello AS
  • Allergy Therapeutics PLC
  • Anergis S.A.
  • Biomay AG
  • Desentum Oy
  • HAL Allergy B.V.
  • Laboratorios LETI S.L.
  • S-TARget therapeutics GmbH

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Allergy